Epirus, Ranbaxy win nod for arthritis drug copy

The drug will be launched in India under the name Infimab by the first quarter of 2015

September 16, 2014 11:42 pm | Updated 11:42 pm IST - BOSTON:

The drug will be launched in India under the name Infimab by the first quarter of 2015

The drug will be launched in India under the name Infimab by the first quarter of 2015

Boston-based biopharmaceutical company Epirus Biopharmaceuticals Inc said India’s drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

The company's Indian partner, Ranbaxy Laboratories Ltd , will sell a copycat version of Johnson & Johnson’s and Merck & Co Inc’s infliximab, an anti-inflammatory drug with annual sales of about $6 billion.

The market for copycat biotech drugs, known as biosimilars, is becoming more lucrative as patents expire on older, high-priced antibody drugs that rank among the pharmaceutical industry's biggest sellers.

Infliximab, sold under the brand name Remicade, is used to treat rheumatoid arthritis, Crohn’s Disease, psoriasis and other inflammatory conditions. In India, it sells at about Rs.70,000 ($1,150) a month. Like its main rivals, Amgen Inc’s Enbrel and AbbVie Inc’s Humira, the drug works by blocking a protein called tumour necrosis factor.

Epirus, which focuses on developing biosimilar drugs for sale, said it would launch the Remicade biosimilar in India under the name Infimab by the first quarter of 2015.

Chief Executive Amit Munshi, citing various estimates, said the Indian market for Remicade was worth $8 million to $10 million a year. He declined to say how much Infimab would cost or to estimate how many patients might use the drug.

The drug will be made in Mumbai by Reliance Life Sciences, part of billionaire Anil Ambani’s Reliance Group Holdings.

Remicade copycats are already being sold elsewhere. South Korean drugmaker Celltrion Inc won approval in July for its version in Japan and is hoping for U.S. approval in 2015. Epirus is also in talks with Ranbaxy, as well as other Indian and international companies, about expanding sales of its biosimilar drugs in other regions, Mr. Munshi said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.